Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.

Liddle RA, Gertz BJ, Kanayama S, Beccaria L, Gettys TW, Taylor IL, Rushakoff RJ, Williams VC, Coker LD.

J Clin Endocrinol Metab. 1990 May;70(5):1312-8.

PMID:
2186058
2.

Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans.

Hildebrand P, Ensinck JW, Ketterer S, Delco F, Mossi S, Bangerter U, Beglinger C.

J Clin Endocrinol Metab. 1991 May;72(5):1123-9.

PMID:
2022712
3.

Inhibition of cholecystokinin-stimulated pancreaticobiliary output in man by the cholecystokinin receptor antagonist MK-329.

Cantor P, Olsen O, Gertz BJ, Gjorup I, Worning H.

Scand J Gastroenterol. 1991 Jun;26(6):627-37.

PMID:
1713709
4.
6.
7.

The effect of the cholecystokinin receptor antagonist MK-329 on meal-stimulated pancreaticobiliary output in humans.

Cantor P, Mortensen PE, Myhre J, Gjorup I, Worning H, Stahl E, Survill TT.

Gastroenterology. 1992 May;102(5):1742-51.

PMID:
1568584
8.
9.

Cholecystokinin receptor antagonist loxiglumide modulates plasma levels of gastro-entero-pancreatic hormones in man. Feedback control of cholecystokinin and gastrin secretion.

Schmidt WE, Creutzfeldt W, Höcker M, Nustede R, Choudhury AR, Schleser A, Rovati LC, Fölsch UR.

Eur J Clin Invest. 1991 Oct;21(5):501-11.

PMID:
1752290
10.

Effects of cholecystokinin and glucagon-like peptide 1 on the secretion of pancreatic polypeptide in mice.

Ahrén B, Gingerich RL, Havel PJ.

Regul Pept. 1995 Nov 10;59(3):297-302.

PMID:
8577934
11.

Effect of CCK on insulin, glucagon, and pancreatic polypeptide levels in humans.

Schmid R, Schusdziarra V, Schulte-Frohlinde E, Maier V, Classen M.

Pancreas. 1989;4(6):653-61.

PMID:
2682604
12.

Effects of non-peptidal CCK receptor antagonist (L-364,718) on pancreatic responses to cholecystokinin, gastrin, bombesin, and meat feeding in dogs.

Konturek SJ, Tasler J, Konturek JW, Cieszkowski M, Szewczyk K, Hładij M, Anderson PS.

Gut. 1989 Jan;30(1):110-7.

13.

Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man.

Ahrén B, Pettersson M, Uvnäs-Moberg K, Gutniak M, Efendic S.

Diabetes Res Clin Pract. 1991 Sep;13(3):153-61.

PMID:
1683622
14.

Cholecystokinin is not a major determinant for the changes in beta-cell function seen after pancreatico-biliary diversion in rats.

Gasslander T, Lilja I, Smeds S, Lundquist I, Ihse I.

Diabetes Res. 1991 Nov;18(3):135-42.

PMID:
1841824
15.

Effects of CCK on pancreatic function and morphology.

Niederau C, Lüthen R, Heintges T.

Ann N Y Acad Sci. 1994 Mar 23;713:180-98. Review.

PMID:
8185159
16.

Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans.

Liddle RA, Rushakoff RJ, Morita ET, Beccaria L, Carter JD, Goldfine ID.

J Clin Invest. 1988 Jun;81(6):1675-81.

17.

Cholecystokinin in the regulation of gastric acid and endocrine pancreatic secretion in humans.

Konturek JW, Stoll R, Gutwinska-Konturek M, Konturek SJ, Domschke W.

Scand J Gastroenterol. 1993 May;28(5):401-7.

PMID:
8511500
18.
19.

L-364,718, a new CCK antagonist, inhibits postprandial pancreatic secretion and PP release in dogs.

Hosotani R, Chowdhury P, Rayford PL.

Dig Dis Sci. 1989 Mar;34(3):462-7.

PMID:
2646088
20.

Endogenous opioids modulate the effect of cholecystokinin on insulin release in dogs.

Schusdziarra V, Lenz N, Rewes B, Pfeiffer EF.

Neuropeptides. 1984 Nov;4(6):507-17.

PMID:
6096758

Supplemental Content

Support Center